# Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.

> **NCT02624557** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 23 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Alpelisib

## Key facts

- **NCT ID:** NCT02624557
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-21
- **Primary completion:** 2017-10-01
- **Final completion:** 2017-10-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2020-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02624557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02624557, "Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02624557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*